Seelos Therapeutics has been selected to present a poster from a study of SLS-005 in a tauopathy model of Alzheimer’s disease at the Society for Neuroscience’s Neuroscience 2023 meeting November 11-15, in Washington, D.C. Non-human primates were administered SLS-005 weekly and demonstrated a 46% reduction in tau protein and an 18% reduction in NfL neurofilament light chain protein biomarker from baseline values over 6 months in a preliminary analysis. Previously, SLS-005 demonstrated an efficacious reduction of mHTT, the mutant protein implicated in Huntington’s disease, by 77% in striatum and 84% in cortex, along with a 100% reduction of Darpp-32, which is associated with neuronal dysfunction in striatum of the R6/2 severe HD model. SLS-005 is an investigational treatment and is not currently approved by any health authority for medicinal use.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SEEL:
- Seelos Therapeutics retains Canaccord Genuity to review potential partnerships
- Empery alleges critical clinical trial misrepresentations by Seelos Therapeutics
- Seelos Therapeutics reports preclinical data from an in vivo study of SLS-005
- Biotech Alert: Searches spiking for these stocks today
- Enphase Energy upgraded, Brighthouse downgraded: Wall Street’s top analyst calls
